Adding Adjuvant Increases the Benefit of Influenza Vaccine in Young Children

Vaccine efficacy and immunogenicity were both improved when trivalent inactivated influenza vaccine was adjuvanted with an oil-in-water emulsion.

In the U.S., two types of influenza vaccine are approved for children: injectable trivalent inactivated vaccine (TIV) for those aged >6 months and inhaled live attenuated vaccine for those aged >2 years. TIV is not as immunogenic and protective in young children as in older individuals, but it is the only choice for children aged 6 months to 2 years. Adjuvanted vaccines hold promise for improving effectiveness, and influenza preparations containing an oil-in-water emulsion — although not approved in the U.S. — have been used in other countries. In a recent manufacturer-sponsored study conducted in Finland and Germany, researchers studied the effect of adding one such emulsion, MF59, to TIV.

During the 2007–2008 and 2008–2009 influenza season…

Reviewing Author

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

Robert S. Baltimore, MD

Disclosures

Editorial BoardsInfectious Diseases in Children

Leadership Positions in Professional SocietiesMember Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease

Adding Adjuvant Increases the Benefit of Influenza Vaccine in Young Children

Topics

Reviewing Author